Novo Nordisk A/S
NONOF
$49.45
-$0.07-0.14%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 46.79B | 46.70B | 45.46B | 43.59B | 42.09B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 46.79B | 46.70B | 45.46B | 43.59B | 42.09B |
| Cost of Revenue | 8.25B | 7.76B | 7.16B | 6.69B | 6.32B |
| Gross Profit | 38.54B | 38.93B | 38.30B | 36.90B | 35.77B |
| SG&A Expenses | 10.28B | 10.51B | 10.48B | 9.94B | 9.76B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -11.10M | 35.54M | 50.42M | -11.52M | 73.16M |
| Total Operating Expenses | 25.52B | 24.17B | 23.16B | 21.81B | 21.14B |
| Operating Income | 21.26B | 22.53B | 22.30B | 21.78B | 20.95B |
| Income Before Tax | 19.69B | 19.44B | 20.51B | 19.03B | 18.45B |
| Income Tax Expenses | 4.24B | 4.15B | 4.33B | 3.98B | 3.80B |
| Earnings from Continuing Operations | 15.45K | 15.30K | 16.18K | 15.05K | 14.65K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.45B | 15.30B | 16.18B | 15.05B | 14.65B |
| EBIT | 21.26B | 22.53B | 22.30B | 21.78B | 20.95B |
| EBITDA | 23.17B | 24.30B | 23.86B | 22.99B | 21.93B |
| EPS Basic | 3.48 | 3.44 | 3.64 | 3.38 | 3.29 |
| Normalized Basic EPS | 3.06 | 3.16 | 3.10 | 3.00 | 2.92 |
| EPS Diluted | 3.47 | 3.44 | 3.64 | 3.38 | 3.28 |
| Normalized Diluted EPS | 3.05 | 3.15 | 3.09 | 3.00 | 2.91 |
| Average Basic Shares Outstanding | 17.77B | 17.77B | 17.78B | 17.80B | 17.82B |
| Average Diluted Shares Outstanding | 17.79B | 17.80B | 17.81B | 17.83B | 17.85B |
| Dividend Per Share | 1.81 | 1.70 | 1.70 | 1.63 | 1.63 |
| Payout Ratio | 49.09% | 49.60% | 44.93% | 48.33% | 44.06% |